Angela Waldrop
Psychiatric/Mental Health · Madison, ALNPI 1851942486
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 432 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Supernus Pharmaceuticals, Inc. at 25.1% of the total.
Across 432 payments — averaging $14.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$2K
- AbbVie$1K
- Axsome Therapeutics, Inc.$599
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$441
- Otsuka America Pharmaceutical, Inc.$412
- Corium, LLC$405
- plus $2K from 17 others
What the payments were for
- Food & beverage$6,452100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 111 | $1,621 |
| AbbVie | 95 | $1,449 |
| Axsome Therapeutics, Inc. | 45 | $599 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 35 | $441 |
| Otsuka America Pharmaceutical, Inc. | 25 | $412 |
| Corium, LLC | 36 | $405 |
| Johnson & Johnson | 12 | $212 |
| Lundbeck LLC | 10 | $192 |
| Alkermes, Inc. | 9 | $180 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $176 |
| Ironshore Pharmaceuticals Inc. | 12 | $175 |
| Tris Pharma Inc | 10 | $169 |
| Vanda Pharmaceuticals Inc. | 3 | $92 |
| Neos Therapeutics, LP | 4 | $79 |
| Sunovion Pharmaceuticals Inc. | 5 | $60 |
| Almatica Pharma LLC | 3 | $52 |
| Neurocrine Biosciences, Inc. | 1 | $34 |
| Neuronetics, Inc. | 1 | $28 |
| Noven Therapeutics, LLC | 1 | $24 |
| Bausch Health US, LLC | 1 | $19 |
| Adlon Therapeutics L.p. | 1 | $16 |
| Vertical Pharmaceuticals, LLC | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$206
How this compares
$6,464 in reported general payments places this provider in the 85th percentile of 378 psychiatric/mental health providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 13 | $397 |
| Buspirone Hcl | 16 | $341 |
| Aripiprazole | 17 | $169 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Madison
- Keith WattsMadison$13K
- Michelle PrattMadison$13K
- Stephanie KitchenMadison$9K
- Stephanie McLaughlinMadison$8K
- William CrainMadison$7K
- Lauren RossMadison$7K
- Kelly GreerMadison$6K
- Laura GrahamMontgomery$80K
- Yuliya SpencerBirmingham$65K
- Keri BarrBay Minette$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.